We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Poolbeg Pharma Plc | LSE:POLB | London | Ordinary Share | GB00BKPG7Z60 | ORD 0.02P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.66% | 7.65 | 7.60 | 7.70 | 7.70 | 7.65 | 7.70 | 64,978 | 08:19:14 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 0 | -3.93M | -0.0079 | -9.68 | 38M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/10/2024 13:28 | Is Pogue a bot? I've never seen anyone reply so quick in a share chat room. He's not bothered though honest lol | malcolmz1 | |
14/10/2024 10:56 | Divide that by 1/2 because of the . | chica1 | |
14/10/2024 10:00 | You guys are funny. I took some profits and when I saw you guys talking the share down I increased my position. Thanks for all your hard work. Strong buy | spuddymadrid | |
14/10/2024 09:26 | "I sold shares at 15.12 and rebought at 8.6." So spuddy you're basically a pump and dumper yourself. | chica1 | |
14/10/2024 09:15 | Are you referring to yourself Malcolm. I sold shares at 15.12 and rebought at 8.6. We all have our opinions. No more than that. My opinion is that this is a strong buy. We will see who is proved right. Good luck with your share bashing policy !! | spuddymadrid | |
14/10/2024 08:52 | You can't filter the facts. This has burnt 10m since it listed and is sitting at over 20% discount to ipo price. Another example of someone who hasn't banked a penny when the share price was up 50%. Some people never learn. | malcolmz1 | |
14/10/2024 08:45 | How can it be a strong buy when the share price is in a bearish market structure? | malcolmz1 | |
14/10/2024 08:24 | As I said before I still have half my Hvivo distribution shares. I'm holding the rest as a punt. | chica1 | |
14/10/2024 08:22 | Shorters still looking for cheap shares. Entertaining to see. Strong buy. | spuddymadrid | |
14/10/2024 07:50 | Hope people didn't get spiked by his comments | chica1 | |
14/10/2024 07:30 | Man shouldn't be allowed near any Board of Directors | chica1 | |
14/10/2024 07:25 | Back in the 7s but don't worry the telegram group think there's a NASDAQ listing before Christmas (not sure what year though) | malcolmz1 | |
14/10/2024 07:23 | When Cathal starts ramping its tile to sell | malcolmz1 | |
14/10/2024 07:21 | Cathal Friel speaking out of his piehole again. | chica1 | |
13/10/2024 08:54 | Peterrr3 I go to plenty events to window shop, going to an event does not mean there is a fundraise going to happen, I suggest you are taking one presentation out of context and extrapolating to the moon. I don’t see where they need the funds to be honest. They started out 3 years ago with around £20 million and now have around £10 million and are trailing POLB001 with 2 pharma companies’ drugs which suggests they are in advanced talks as if they goto human trial, they have done the In Vivo animal trial, there would have to be a contract signed setting out the partnership/selling deal should the result be positive as is normal in these situations in industry. No pharma company would want to increase the value of a 3rd party drug by proving it successful without having a price fixed beforehand. Why fundraise when you are that close to a massive monetisation of your lead asset? Why are they trying to find an orphan drug to sell? Well to make money perhaps? POLB have a pipeline of drugs they develop and sell/partner. Pentoxifylline has past phase II so they don’t need to put it through a trial. I don’t know what the deal will be with the owner but I cannot see POLB buying it unless they have a buyer. I suggest the most likely is a partnership where POLB help sell the drug and share in the profits. This is a capital light company they don’t spend money unless they have to bringing on drugs, have you seen the very small quantities of cash they have spent on the existing drugs in the pipeline? The fact they have spent only £10 million or so over 3 years is a clue. As I said I have listened to the Liam Trimble go on about POLB’s encapsulation tech being used in a trail later this year all 43 seconds off it and did not get excited about at the time as an oral encapsulation trial was being planned from the beginning of this year and was initially down to happen July/August so not seeing what the issue is, nothing new in it. The cost will be small and is being tested for use with another company’s drug they will contribute in some way same as those pharmas running the POLB001 trials did. The trial is very simple for encapsulation. Volunteer comes into medical establishment, pops a pill come backs next day to get a blood test to see if the drug has dispersed in their system, you really think they need a fundraise for this and it hasn’t been planned for? It is not the drug that’s being tested its oral encapsulation so not dangerous or expensive do you really think a sudden fundraise is needed for that as it has been planned for for a long time? As I said POLB does not have an obesity drug it’s the encapsulation that is being trailed. Should the trial work then there is a vast market out there for oral encapsulation way outside obesity drugs. Really cant see what you are going on about there. So to summarise why do you think they need a fundraise when they are getting close to a deal on POLB001? Oral encapsulation has been planned for trial for a long time and is not expensive to do. Pentoxifylline does not belong to POLB, they have an option on it and is past phase II so what cash do they need to spend as the option will more than likely be on a deal to sell in partnership with current owner and they dont need to conclude the deal if they see no buyers. | pogue |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions